Document Detail


Clonal evolution in chronic myelogenous leukemia.
MedLine Citation:
PMID:  15271399     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clonal evolution (CE) may be a marker of disease progression in chronic myelogenous leukemia (CML) and is thought to reflect the genetic instability of the highly proliferative CML progenitors. The frequency of CE increases with advancing stage, rising from 30%in accelerated phase and up to 80% in blast crisis. Given its association with disease progression, CE is considered a feature that defines accelerated-phase CML; however, not all studies have demonstrated a uniformly poor outcome for patients with CE. Chromosomal abnormalities in Ph chromosome negative metaphases increasingly have been recognized in patients treated with imatinib. The true incidence of this phenomenon is not clear but appears to occur in 2% to 17% of imatinib-treated patients. Regardless of the precise mechanism and the long-term clinical implications, the findings described in this article underscore the importance of routine cytogenetic analysis for patients treated with imatinib. The continued study of these phenomena will help us to understand better the pathogenesis of CML and improve the long-term treatment of patients with CML.
Authors:
Jorge Cortes; Michael E O'Dwyer
Related Documents :
2790739 - Prognostic significance of single chromosome abnormalities in preleukemic states.
3472649 - Trisomy 9 in hematologic disorders: possible association with primary thrombocytosis.
18158579 - Detection of cd55- and cd59-deficient granulocytic populations in patients with myelody...
15468339 - Stability of leukemia-associated aberrant immunophenotypes in patients with acute myelo...
21524949 - Small-incision orbicularis-levator fixation technique: a modified double-eyelid blephar...
11166459 - Clonality analysis using x-chromosome inactivation patterns by humara-pcr assay in fema...
2790739 - Prognostic significance of single chromosome abnormalities in preleukemic states.
19300159 - Normalization of conjunctival flora after dacryocystorhinostomy.
19626399 - Interleukin-6 is a stronger prognostic predictor than high-sensitive c-reactive protein...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  18     ISSN:  0889-8588     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-07-23     Completed Date:  2004-09-23     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  671-84, x     Citation Subset:  IM    
Affiliation:
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. jcortes@mdanderson.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology,  therapeutic use
Chromosome Aberrations
Clone Cells / drug effects,  pathology
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy,  mortality,  pathology*
Prognosis
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Monitoring of minimal residual disease in chronic myeloid leukemia.
Next Document:  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.